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Abstract:  
Hypertension in children is common, and the prevalence of primary hypertension is increasing with the obesity 
epidemic and changing dietary choices. Careful measurement of blood pressure is important to correctly diagnose 
hypertension, as many factors can lead to inaccurate blood pressure measurement. Hypertension is diagnosed based 
on comparison of age, sex, and height-based norms with the average systolic and diastolic blood pressures on three 
separate occasions. 
In the absence of hypertensive target organ damage (TOD), stage I hypertension is managed first by diet and 
exercise, with the addition of drug therapy if this fails. First-line treatment of stage I hypertension with TOD and 
stage II hypertension includes both lifestyle changes and medications. First-line agents include angiotensin-
converting enzyme (ACE) inhibitors, thiazide diuretics, and calcium-channel blockers. Hypertensive emergency 
with end-organ effects requires immediate modest blood pressure reduction to alleviate symptoms. This is usually 
accomplished with IV medications. Long-term reduction in blood pressure to normal levels is accomplished 
gradually.  
Specific medication choice for outpatient hypertension management is determined by the underlying cause of 
hypertension and the comparative adverse effect profiles, along with practical considerations such as cost and 
frequency of dosing. Antihypertensive medication is initiated at a starting dose and can be gradually increased to 
effect. If ineffective at the recommended maximum dose, an additional medication with a complementary 
mechanism of action can be added. 
Key Points: 
Elevated blood pressure is an increasingly common, but still under-recognized, problem in children. 
First line management of ambulatory hypertension is generally centered on lifestyle change, but end-organ damage 
or significant hypertension may require immediate pharmacologic intervention. 
ACE inhibitors, thiazide diuretics, and calcium-channel blockers may all be considered reasonable first-line choices 
for children requiring drug treatment of hypertension. 
1. Disease Background
1.1 Epidemiology and Definitions 
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Normal blood pressure in children is defined as SBP and DBP that are <90th percentile for age, gender, and height 
[1]. Prehypertension is defined as an average SBP or DBP levels on one occasion that are <95th percentile but ≥ 
either 90th percentile or 120/80 mmHg, whichever is lower [1]. Hypertension in children is defined as an average 
systolic blood pressure (SBP) and/or diastolic blood pressure (DBP) greater than or equal to the 95th percentile for 
sex, age, and height – accurately measured on three separate occasions [1]. Hypertension is classified as stage I if 
the average SBP or DBP is between the 95th percentile and the 99th percentile + 5 mmHg, and stage II hypertension 
if the average of either SBP or DBP exceeds the 99th percentile + 5 mmHg. 
Epidemiological studies indicate that pediatric hypertension is becoming more common. Historically, prevalence 
rates were thought to be around 1%, but data from the National Health and Nutrition Examination Survey 
(NHANES) from 1998-2012 indicate that 1.6-3.1% of children aged 8-17 have hypertension, and up to 15% of 
adolescents have prehypertension or hypertension [2]. A screening study of 5,102 children aged 10-19 years in the 
Houston public schools demonstrated that 4.5% of children had hypertension, and 11% with BMI greater than or 
equal to the 95th percentile had hypertension [3]. A repeat study in the Houston schools of 6,790 adolescents aged 
11-17 showed that 81.1% of children had normal BP, 15.7% had prehypertension, and 3.2% had hypertension [4].  
The increase in the prevalence of hypertension is due in large part to the increased prevalence of obesity among 
children and adolescents [5]. With this change has come a shift in the most common etiology of hypertension: 50-
90% of patients diagnosed with pediatric hypertension at referral centers have primary (essential) hypertension [6]. 
The association of hypertension with obesity is observed as early as five years of age, and is common in patients 
greater than ten years of age [7, 8].  The increased quantity of sodium and high fructose corn syrup (HFCS) in the 
typical diet of US children over the past 20-40 years is also thought to have contributed to the rise in childhood 
hypertension [9, 10]. 
Though primary hypertension is increasingly the cause of high blood pressure in children, secondary hypertension 
remains more common in children than it is in adults, and is the predominant cause of hypertension in children less 
than 6 years of age [11]. The diagnostic evaluation for hypertension should be guided by history, physical 
examination, and patient characteristics. The specific laboratory and imaging workup of confirmed hypertension is 
reviewed in detail in “The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in 
Children and Adolescents” [1]. 
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White coat hypertension (WCH) is an especially common cause of elevated blood pressure measurements, 
accounting for up to 46% of patients referred for evaluation of hypertension [12]. Patients with WCH have elevated 
blood pressures in a medical setting, but outside this environment their blood pressures are normal [1]. In adults, 
there is evidence that WCH is a non-benign condition with high risk of progression to true hypertension; it is 
unknown whether this holds true for children with WCH [13, 14]. While current guidelines do not recommend a 
diagnostic workup for children with WCH, this condition may represent an intermediate state between normal blood 
pressure and hypertension [1, 15]. Thus, patients with WCH may benefit from modification of unhealthy lifestyle 
habits and monitoring for worsening hypertension. 
Masked hypertension can be considered to be the inverse of white coat hypertension, with normal in-office blood 
pressures but elevated average blood pressures on home monitoring or 24-hour ambulatory blood pressure 
monitoring (ABPM). Populations at high risk of masked hypertension should be routinely screened with ABPM or 
home BP monitoring in order to correctly identify and respond to this entity. Some examples of at-risk populations 
include kidney transplant recipients, pediatric dialysis patients, and children with chronic kidney disease (CKD) or 
sickle cell disease. In at-risk populations, the prevalence of masked hypertension has ranged from 10-22%, and 
masked hypertension is associated with left ventricular hypertrophy in these patients [16]. Further study is needed to 
determine which additional groups of children may benefit from screening for masked hypertension.  
1.2. Pathophysiology 
1.2.1 Primary Hypertension 
Primary hypertension has a polygenic inheritance pattern, though family history does play a prominent role. High 
sodium intake, high fructose corn syrup intake, and increased sympathetic tone have been connected to the 
development of primary hypertension in obese patients.[9, 10] Obesity itself adds to the systemic load against which 
the heart pumps due to the additional vasculature needed to supply extra body mass. In obese adolescents, blood 
pressure falls by an average of 1-2 mmHg per pound of weight lost and rises by an average of 1.5 mmHg per 1,000 
mg additional daily sodium intake [9, 17]. 
Uric acid is frequently elevated in patients with primary hypertension, and reduction of uric acid levels in 
hypertensive and prehypertensive adolescents may reduce blood pressure [18, 19]. However, these were small, 
proof-of-concept studies, and this finding has not been replicated on a large scale. Animal studies show that elevated 
uric acid levels cause hypertension through reduction in endothelial nitric oxide and stimulation of renin, with 
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prolonged exposure resulting in sodium-sensitive hypertension due to endothelial dysfunction which does not 
respond to reduction of uric acid levels [18, 20]. 
1.2.2 Secondary Hypertension 
A full discussion of the pathophysiology of secondary hypertension is beyond the scope of this review. In the 
monogenic hypertension states, single gene defects lead to inappropriate renal sodium retention (via any one of 
multiple pathways), leading to volume retention and intravascular volume overload [21]. In disorders which activate 
the renin-angiotensin-aldosterone axis, such as renovascular hypertension and hypertension mediated by renal 
parenchymal disease, peripheral vasoconstriction due to angiotensin II is added to the effect of sodium retention due 
to increased aldosterone production. Other major mechanisms of secondary hypertension include catecholamine 
excess due to tumors such as pheochromocytoma or neuroblastoma, and iatrogenic causes including medications 
(see table 1). If a patient is found to have a secondary hypertensive state, the specific etiology of the hypertension 
determines the subsequent choice of treatment, including first- and second-line drug classes and/or non-
pharmacologic treatments as indicated.   
1.3 Clinical Presentation and Diagnosis 
Hypertension can present with nonspecific symptoms (e.g. headache, fatigue), but commonly remains asymptomatic 
until the blood pressure reaches very high levels, at which point severe headache, blurry vision, fatigue, or confusion 
may develop [22]. It is therefore recommended that blood pressure be checked routinely at each well-child visit for 
patients ≥ 3 years of age, with screening for patients <3 years of age only if they have specific risk factors for 
hypertension. Blood pressure should be compared to age, gender, and height specific norms so that an elevated 
blood pressure is not overlooked [1]. The diagnosis of prehypertension can be made on the basis of the average of 
blood pressure measurements on a single occasion, while diagnosis of hypertension requires measurements on three 
separate occasions [1].  
The accuracy of blood pressure measurement is essential to making a correct diagnosis. Casual blood pressures 
measured by auscultation have low inter-operator reliability. Mercury-containing sphygmomanometers are preferred 
for accuracy, though environmental and occupational safety concerns limit their use. Aneroid sphygmomanometers 
are an acceptable alternative, but they need to be calibrated frequently, which is often not done in clinical practice. It 
is recommended that blood pressure measurements be obtained in a controlled environment, after five minutes of 
rest, with the patient seated and with the arm supported at heart level [1]. Single measures of blood pressure in the 
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clinic can be affected by many variables, including terminal digit preference by the clinician, improper cuff size, 
incorrect patient position, and the white coat effect. Repeat blood pressure measurements increase precision and 
reproducibility of results, and taking at least three measurements per clinic visit is recommended [1, 23, 24]. 
Oscillometric blood pressure devices measure the point of greatest oscillation in the arterial wall, which is the mean 
arterial pressure. From this value, systolic and diastolic blood pressures are calculated using proprietary algorithms.  
Different device manufacturers use different algorithms to calculate the SBP and DBP, and even within 
manufacturers, different algorithms may be used from device to device. Some are known to overestimate SBP by as 
much as 10 mmHg, while others may underestimate SBP [25, 26]. It is recommended that any blood pressure which 
exceeds the 90th percentile for age, gender, and height using an oscillometric device be confirmed by auscultation 
[1]. 
Twenty-four-hour ambulatory blood pressure monitoring (ABPM) is fast becoming the gold standard for 
determination of hypertension in both children and adults, and seems to correlate better with outcomes [27]. 
However, it is primarily restricted to subspecialty use in pediatrics.  
2. Disease management
2.1 Disease management overview 
The long-term effects of childhood hypertension are largely unknown, as has been detailed in the recent United 
States Preventative Services Task Force (USPSTF) report, which highlights the need for more evidence to fully 
understand the relationship between childhood hypertension and cardiovascular disease [27, 28]. The development 
of target organ damage, including carotid intima-media thickening, left ventricular hypertrophy, hypertensive 
nephropathy, and retinopathy are all well-established consequences of childhood hypertension. A recent study of 1.3 
million children with military insurance found that 8% of children diagnosed with hypertension had hypertensive 
target organ damage on echocardiography [29]. In addition, longitudinal studies have shown that childhood 
hypertension frequently persists into adulthood, and that childhood hypertension is the strongest predictor of adult 
hypertension [30]. The best evidence for rates of persistence of hypertension comes from the i3C cohort, a subgroup 
analysis of 1,602 children with elevated blood pressure from four prospective studies: the Bogalusa Heart Study, the 
Cardiovascular Risk in Young Finns Study, the Muscatine Study, and the CDAH study. Analysis showed that 60% 
(969/1602) of children with elevated blood pressure had continued blood pressure elevation as adults, and that 
improvement in blood pressure tracked most closely with decrease in BMI [31].  
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In treatment of hypertension, the Fourth Report [1] states that goal blood pressure should be below the 95th 
percentile for children who have primary hypertension without end-organ damage, and below the 90th percentile for 
children who are at high risk for cardiovascular morbidity and mortality (children with chronic kidney disease 
[CKD], diabetes mellitus, or a renal transplant) [1]. The 2009 European Society of Hypertension pediatric guidelines 
recommend goal blood pressures below the 90th percentile for children with uncomplicated primary hypertension, 
below the 75th percentile for diabetic or CKD patients without proteinuria, and below the 50th percentile in diabetic 
or CKD patients with proteinuria [27].  
Hypertension in children is frequently under-recognized and undertreated. The Chronic Kidney Disease in Children 
study showed that even in children with CKD, who have a 37% prevalence of hypertension, 39% of patients with 
confirmed hypertension were not receiving antihypertensive drugs [32]. A study of 1.3 million children with military 
health insurance found that only 34% of children diagnosed with hypertension underwent echocardiography, and 
only 38.9% of children diagnosed with hypertension received an antihypertensive medication [29]. Blood pressures 
should be monitored regularly in follow-up to determine if the intervention is resulting in reduction of blood 
pressures to goal levels. If target organ damage is identified, it should also be monitored periodically for progression 
or regression. 
2.2 Non-pharmacologic treatment 
Dietary modification, such as the Dietary Approaches to Stop Hypertension (DASH) diet, weight loss, and regular 
aerobic exercise are the cornerstones of therapy for primary hypertension, and can be helpful in many other forms of 
hypertension as well [33]. These so-called therapeutic lifestyle changes (TLC) should be applied as monotherapy 
when either prehypertension or uncomplicated stage I hypertension is diagnosed. TLC should be prescribed together 
with anti-hypertensive medications when blood pressure is stage II or greater, or for stage I hypertension if 
compelling indications for pharmacologic treatment are present. Such indications include diabetes mellitus, pre-
existing CKD, or evident hypertensive target organ damage. Hypertensive target organ damage seen in children can 
include retinopathy, carotid intima-media thickening, left ventricular hypertrophy, or hypertensive nephropathy. 
3. Outpatient pharmacologic therapy for hypertension (see table 2 for specific agents and dose ranges)
3.1 Overview of pediatric drug treatment of hypertension 
Many antihypertensive medications have not been formally studied in children, which has led to the widespread use 
of antihypertensive agents without FDA-approved pediatric labeling. A recent study showed that 7% of drugs used 
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in children were neither labeled for pediatric use nor considered recommended for use in children, and 29% of drugs 
used in children under 6 years of age were not indicated for use in that age group [34]. In addition to a lack of 
labeling, many drugs lack evidence for their efficacy in children. A recent Cochrane review identified 21 trials of 
antihypertensive drugs in pediatrics, of which only 5 compared the antihypertensive with placebo [35]. This review 
highlights the lack of evidence for the efficacy of many commonly used antihypertensive medications in children. 
While the 1997 Food and Drug Administration Modernization Act (FDAMA) resulted in increased pediatric trials of 
many newer medications, there are currently no incentives for industry-sponsored trials of older medications in 
children. Thus, the discussion of many of the medications below is off-label and is based on adult data, clinical 
experience, and expert opinion [1]. The discussions of the drug classes below are not intended as a comprehensive 
reference; readers are directed to package labeling and reliable electronic resources for a complete listing of 
warnings and contraindications. 
3.2 Calcium Channel Blockers 
3.2.1 Mechanism of action 
Calcium channel blockers inhibit calcium channels within smooth muscle cells in the vasculature, resulting in 
decreased vasoconstriction and thus decreased peripheral vascular resistance. 
3.2.2 Indications and contraindications 
This class of medications has relatively few absolute contraindications, and is among the first-line agents for the 
treatment of hypertension. The adverse effects of calcium channel blockers are generally minor and include 
peripheral edema and headache. These are due to the peripheral vasodilation caused by these agents [35, 36].  If a 
primary care physician is uncertain how to proceed with hypertension workup, but needs to start therapy (e.g. due to 
stage II or symptomatic hypertension) while a subspecialist referral is pending, calcium-channel blockers are a 
reasonable first choice, as their use generally does not interfere with subsequent evaluation of the renin-angiotensin-
aldosterone axis or measurement of metanephrines and/or catecholamines if indicated.  Hypotension is unlikely with 
use of standard starting doses. Caution should be exercised when prescribing extended-release nifedipine by 
computerized order entry, as immediate-release and extended-release nifedipine preparations may be easily confused 
in a computer order system. 
3.2.3 Relevant within class differences 
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Amlodipine is dosed once daily; full effect is commonly not seen until the after steady state is reached, often after 5-
6 days of therapy, due to its long half-life of 36-45 hours [36]. A multicenter pharmacokinetics study showed that 
weight-adjusted clearances and volume of distribution were significantly greater in younger children, suggesting a 
need for higher amlodipine mg/kg/day doses in children less than 6 years of age [37]. Nifedipine is a short-acting 
calcium channel blocker which is available in an extended release formulation; dosing recommendations are 
available for children 6 years of age and older. The short-acting form, however, should be used with some caution as 
it has the potential to cause overly rapid drops in blood pressure [36]. Nifedipine’s extended release formulation is 
available in tablet form only, but is sometimes preferable to amlodipine as it reaches steady state faster than 
amlodipine due to nifedipine’s short half-life of 2-4 hours [36].  Felodipine is only available as an extended-release 
formulation for which the dosage form must be swallowed whole, limiting utility in younger children. Isradipine 
must be dosed 3-4 times daily and there is less experience with its use in children. Non-dihydropyridines, such as 
verapamil and diltiazem, have a negative inotropic effect and are therefore more commonly used for angina and rate 
control of atrial fibrillation than for hypertension [36].  Additionally, there are little data or experience available on 
the use of non-dihydropyridines for hypertension in children. 
3.3 ACE inhibitors 
3.3.1 Mechanism of action 
ACE inhibitors prevent the conversion of angiotensin I to angiotensin II by blocking the effects of angiotensin 
converting enzyme. Angiotensin II causes direct systemic vasoconstriction and sodium retention in the renal tubules, 
both by direct action in the proximal tubule and by stimulation of aldosterone production in the adrenal cortex. 
Angiotensin converting enzymes also catalyze the breakdown of bradykinin, and buildup of this vasoactive 
substance in patients taking ACE inhibitors is thought to contribute to their beneficial effects on cardiac remodeling.  
By reducing intraglomerular pressures, ACE inhibition extends nephron lifespan and decreases proteinuria in 
patients with albuminuria due to CKD or diabetes mellitus.  
3.3.2 Indications and contraindications 
ACE-inhibitors are teratogenic and should not be used by pregnant women or females who are at risk of becoming 
pregnant [38]. They can precipitate acute kidney injury (AKI) in patients with bilateral renal artery stenosis, or for 
patients with a solitary kidney who have renal artery stenosis. They are known to cause hyperkalemia through their 
inhibition of aldosterone production, and can also decrease glomerular filtration rate (GFR), though this decrease is 
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usually mild and acceptable in patients with normal baseline renal function. They should be avoided in the setting of 
acute kidney injury as they can decrease GFR and prolong recovery. 
ACE inhibitors are generally well-tolerated, and the common adult side-effect of chronic cough was seen in less 
than 3% of a pediatric population treated with enalapril [39]. Given the beneficial effects on cardiac function and 
remodeling, these drugs are considered the drug of choice for patients with diminished cardiac function or left 
ventricular hypertrophy. Preliminary data indicate improvement in lipid profile and insulin resistance in obese 
children with metabolic syndrome receiving ACE inhibitors [40]. Their renal protective effects make them the drug 
of choice for patients with CKD or diabetes mellitus, and they are a good first-line drug for patients who lack the 
contraindications above. In addition to their antihypertensive effect, ACE inhibitors are often used as adjunctive 
agents for proteinuria control in children with nephrotic syndrome or other proteinuric renal disease states.  
3.3.3 Relevant within class differences 
Of the ACE inhibitors, captopril is the oldest and best-studied in children, and is useful when quick up-titration of 
drug dose is desired [27]. However, its three times daily dosing is inconvenient for patients and families, so once-
daily agents such as lisinopril and enalapril are often used instead, though they have been studied less than captopril 
in children. Lisinopril has been studied in a double-blind placebo-controlled pediatric study and generally costs less 
than newer ACE inhibitors [41]. Enalapril has also been studied in children and is currently the only commercially-
available solution, though at this time the commercial solution may be more costly than compounded lisinopril, for 
example. There is little evidence to suggest that newer, more expensive ACE-inhibitors are superior to the older, 
generic choices. 
3.4 Angiotensin Receptor Blockers (ARBs) 
3.4.1 Mechanism of action 
ARBs block the angiotensin II receptor competitively, blocking vasoconstriction and thus decreasing systemic 
vascular resistance. 
3.4.2 Indications and contraindications 
As with ACE-inhibitors, ARBs are teratogenic, but ARB exposure in pregnancy may be more harmful than that of 
ACE inhibitors [38]. Use in patients with bilateral renal artery stenosis can precipitate acute kidney injury, or for 
patients with a solitary kidney who have renal artery stenosis. They should be avoided in patients with acute kidney 
injury. Adverse effects reported in trials for patients less than 6 years of age have led to some safety concerns [42, 
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43], though they are used with some regularity in this age group. ARBs do not inhibit the breakdown of kinins and 
therefore cause cough less frequently than ACE inhibitors. Although outcome studies in diabetic patients with 
proteinuria are lacking, the similar mechanism of action to ACE inhibitors suggests that ARBs may be the next best 
choice for patients who cannot tolerate ACE inhibitors but otherwise have an indication for an ACE inhibitor [1]. 
3.4.3 Relevant within class differences 
Although ARBs have widely varying half-lives, all are dosed once-daily. Consideration to the improved 
bioavailability of valsartan when administered as a compounded suspension should be given when switching 
between dosage forms. As of the time of this writing, losartan is available as a generic formulation, and may 
therefore be less expensive than other ARBs. If blood pressure control is not sustained for a full 24 hours for patients 
taking losartan, a split dose administered twice daily may be considered. As an aside, this strategy can be employed 
for other once daily antihypertensives as well, though the practitioner should keep in mind that there is a significant 
decrease in adherence to twice daily vs. once daily medication regimens.  
Also now available is aliskiren, a direct renin inhibitor. Its side effect profile is similar to that of ACE inhibitors and 
ARBs. Pediatric phamacokinetic and safety data have been published, but pediatric experience with this medication 
is limited [44]. It is only available in tablet form. 
3.5 Diuretics 
3.5.1 Mechanism of action 
Diuretics decrease left ventricular filling pressure through volume reduction. Long-term use results in decreased 
systemic vascular resistance through unclear mechanisms. 
3.5.2 Indications and contraindications 
Thiazide diuretics are a reasonable first-line choice for the treatment of hypertension in children, though some 
advocate avoiding them in obese patients as they are known to alter glucose metabolism in adults, particularly when 
combined with beta-blockers [27]. Both loop and thiazide diuretics can cause electrolyte disturbances, including 
hypokalemia, so routine electrolyte monitoring is recommended with their use. They can also cause volume 
depletion, so they may not be a good choice for athletes, who are at risk of volume depletion with training and 
exercise. Similarly, they are relatively contraindicated in very young or developmentally delayed children who lack 
independent access to fluids or the ability to respond to increased thirst by increasing fluid intake.  
3.5.3 Relevant within class differences 
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Hydrochlorothiazide is widely available as a tablet or compounded suspension. Chlorothiazide has previously been 
produced as a commercially available solution, though recent drug shortages have impacted its availability. 
Chlorthalidone is thiazide-like and has a longer half-life, but is available as a tablet only. All three decrease calcium 
excretion in the urine. Most thiazide and thiazide-like diuretics do not work well in the setting of GFR less than 30 
ml/min/1.73 m2 due to decreased delivery of the diuretic to the distal tubule, though metolazone does retain its 
activity at lower GFRs.  
Loop diuretics such as furosemide are rarely used for treatment of hypertension alone. Although they are more 
effective diuretics than thiazides and thiazide-like agents, they are less effective as antihypertensive medications. 
Furosemide can cause ototoxicity, especially when given at high doses and in patients with decreased renal function. 
Potassium-sparing diuretics, such as spironolactone and amiloride, are infrequently used in the treatment of 
hypertension except in cases of monogenic hypertension, such as Liddle syndrome or apparent mineralocorticoid 
excess (AME), in which setting they are considered first-line agents. Spironolactone may also be employed as add-
on therapy in the treatment of resistant hypertension. In contrast to the other diuretics, hyperkalemia is a risk with 
these medications.  
3.6 Beta-Blockers 
3.6.1 Mechanism of action 
Beta-adrenergic antagonists block the action of endogenous catecholamines and norepinephrine at their sites of 
action on vascular smooth muscle, myocardium, kidneys, bronchi, and other locations. Their activity in the kidneys 
results in decreased renin secretion. They decrease systemic vascular resistance by decreasing vascular tone, and 
decrease cardiac output by decreasing heart rate and cardiac contractility.  
3.6.2 Indications and contraindications 
The overall side effect profile of beta-blockers in children is considered more significant than that of other 
antihypertensives: they are therefore indicated as second or third line drugs for the treatment of pediatric 
hypertension, unless they are specifically indicated for another reason (e.g. migraine prophylaxis, hypertensive 
cardiomyopathy, etc.). Beta blockers are relatively contraindicated in athletes, as they can decrease maximum sports 
performance and endurance.[1] They are also contraindicated in patients with moderate to severe asthma or chronic 
lung disease, as beta-2 receptor antagonism can precipitate bronchospasm [1]. They should be avoided in insulin-
dependent diabetics, as beta blockade may mask the symptoms of hypoglycemia [1]. Bradycardia is a dose-limiting 
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adverse effect. Abrupt cessation of beta-blockers should be avoided, as rebound hypertension and tachycardia can 
result. This is due to increased sympathetic tone as a result of upregulation of β-adrenoreceptors during chronic 
treatment [45].  
3.6.3 Relevant within class differences 
Cardioselective beta-blockers such as metoprolol and atenolol have a greater affinity for the beta-1 than the beta-2 
receptor, and thus have less effect on bronchial smooth muscle. At higher doses, however, this selectivity is lost. 
Though metoprolol is available as a compounded suspension, it should be noted that this is an immediate-
release/short-acting drug form; only the extended-release metoprolol preparation has been tested in pediatric clinical 
trials [46]. Bisoprolol/HCTZ has been studied in a placebo-controlled trial; it produced a significant reduction of 
diastolic but not systolic blood pressure in children [35, 47]. Labetalol is a combination alpha and beta blocker, and 
is available in IV or enteral form. Propranolol is commercially available as an oral solution. Carvedilol has only 
been studied in children for heart failure.  
3.7 Direct Vasodilators 
3.7.1 Mechanism of action 
This class causes vasodilation of arterioles through direct action on vascular smooth muscle.  
3.7.2 Indications and contraindications 
As a class, direct vasodilators are indicated as a second or third line agent due to their side effect profile. Direct 
vasodilators cause sodium and water retention and result in increased cardiac preload, which may precipitate heart 
failure in patients with poor ventricular compliance. Minoxidil is effective in lowering blood pressure in children 
and adolescents, but the adverse effect of hypertrichosis limits its use to patients with hypertension resistant to other 
agents [1]. Due to rapid onset of action, hydralazine is frequently used as an as-needed medication for acute rises in 
blood pressure. However, it is infrequently useful for chronic management of hypertension, as it requires 3-4x per 
day dosing and patients are often noted to escape its effect over time. Other adverse effects common to both 
medications include flushing, headache, tachycardia, fluid retention, and palpitations [1]. 
3.7.3 Relevant within class differences 
Hydralazine and minoxidil differ in their adverse drug effect profiles and frequency of dosing as noted above. Each 
can be compounded into an oral suspension. One common recipe for compounded hydralazine is only stable for 7 
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days, limiting its usefulness in the outpatient setting, though a compounded hydralazine recipe with ≥ 30 day 
stability is available [48].  
3.8 Alpha blockers 
3.8.1 Mechanism of action 
Peripheral alpha-adrenergic antagonists block the action of endogenous catecholamines and metanephrines on the 
peripheral vasculature, causing peripheral vasodilation and decreased venous return.  
3.8.2 Indications and contraindications 
These medications are generally reserved for resistant hypertension due to their significant side effect profile, 
including first dose syncope, anticholinergic effects, headache, fluid retention, palpitations, drowsiness, weakness, 
and priapism. In adult studies, alpha-adrenergic antagonists increased heart-failure and cardiovascular events when 
used to lower blood pressure [49]. 
3.8.3 Relevant within class differences 
Doxazosin is dosed once daily due to its longer half-life. Prazosin capsules can be opened and the contents mixed in 
food to be given to younger patients. None of the alpha-adrenergic antagonists are available as an oral suspension. 
3.9 Central alpha agonists 
3.9.1 Mechanism of action 
Central alpha agonists decrease central sympathetic outflow by stimulating alpha-2 adrenergic receptors in the 
central nervous system (CNS).  
3.9.2 Indications and contraindications 
Central alpha agonists are well-known to cause rebound hypertension with abrupt cessation of the drug, and cause 
significant drowsiness, which often abates somewhat after several weeks. These and other adverse drug effects limit 
them to use in resistant hypertension, but they can be of particular use in cases of hypertension related to increased 
CNS sympathetic tone, such as in patients with brain injury and autonomic storming or abnormal central nervous 
systems. Additionally, clonidine can be very useful for patients who cannot tolerate enteral intake when given as a 
transdermal continuous-release patch. This class is also often used to treat aggressive behavior in patients with 
attention deficit hyperactivity disorder (ADHD) [1]. 
3.9.3 Relevant within class differences 
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Enteral clonidine must be dosed frequently due to its short half-life, but it is also available as a transdermal 
continuous-release patch, which needs to be changed weekly [1]. The patch cannot be divided or cut due to its 
formulation. Extended-release guanfacine is becoming more widely used as an adjunctive agent for treatment of 
ADHD. Caution should be taken with the rapid cessation of either agent, as rebound hypertension can be seen with 
abrupt discontinuation. 
4. Management of Hypertensive Urgency/Emergency in Pediatrics
Hypertensive urgency is defined as severe hypertension without signs of acute end-organ damage, whereas 
hypertensive emergency is severe hypertension with signs of acute end-organ damage, such as encephalopathy, 
seizures, heart failure, or blindness/severe visual disturbance [27]. Severe hypertension has no specific definition; in 
general, blood pressures need be greater than the cutoff for stage II hypertension to be considered severe. Further 
determination depends on signs, symptoms, and clinical judgement. The rapidity of blood pressure rise, degree of 
rise over baseline, and presence or absence of symptoms are of greater importance than absolute blood pressure 
values. The patient should be evaluated for contraindications to acute reduction of blood pressure, such as 
intracranial mass or injury, and for underlying causes which require a specific treatment approach. More complete 
references are available to guide the practitioner in the evaluation and management of hypertensive urgency and 
emergency [1, 27, 50]. 
Once severe blood pressure elevation has been reliably confirmed and contraindications to blood pressure reduction 
have been rapidly ruled out, blood pressure should be promptly reduced by no more than 25% in the first 6-8 hours, 
with further slow reduction thereafter.  
Consultation with a specialist in pediatric hypertension is advisable to guide therapy. One approach is to administer 
an IV hydralazine dose of 0.2 mg/kg (up to a usual adult dose of 10 – 20 mg), followed by a nicardipine drip starting 
at 0.5-1 mCg/kg/min and titrated to achieve a 25% reduction in blood pressure up to a maximum of 4-5 mCg/kg/min 
[50]. Some concern has recently been raised as to the reliability and safety of IV hydralazine based on a single 
center retrospective study [51].  Nitroprusside infusion or labetalol bolus followed by labetalol infusion are 
alternative strategies (table 3). Caution and close monitoring should be employed with labetalol infusion, as its long 
half-life can lead to greater than anticipated antihypertensive effects with prolonged infusions or with rapid upward 
titration. 
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Rapid reduction of blood pressure beyond 25% risks ischemic stroke and other tissue ischemia due to 
accommodation of cerebral and peripheral vasculature to elevated blood pressures. Blood pressures while on 
continuous antihypertensive drip medications should be monitored frequently, either by continuous intra-arterial 
blood pressure measurement or by cuff measurement at least every 15 minutes. Once blood pressure has been 
stabilized on an antihypertensive medication drip, a longer-acting medication can be started orally and the drip can 
be tapered as oral medications take effect. 
Hypertensive urgency is defined as severe hypertension without acute end-organ effects; it warrants urgent 
evaluation and treatment as the risk for acute end-organ effects in this setting is high. Evaluation for underlying 
cause is central in guiding therapy. Oral agents such as hydralazine, clonidine, isradipine, nicardipine, and minoxidil 
can be used to lower blood pressure acutely, despite less rapid onset as compared to IV medications. If oral intake is 
not tolerated, blood pressure can be reduced using IV agents (e.g. hydralazine, labetalol). As noted above, care 
should be taken to avoid rapidly lowering blood pressure when it is suspected that blood pressure elevation has been 
longstanding [50].   
5. Conclusions
Hypertension in children is common, and the prevalence of primary hypertension is increasing with the obesity 
epidemic and changing dietary choices. Careful measurement of blood pressure and comparison with age, gender, 
and height-based norms is important to correctly diagnose hypertension. White coat hypertension, prehypertension, 
and uncomplicated stage I hypertension should initially be treated non-pharmacologically with weight reduction, 
increased physical activity, and dietary modification including decreased sodium and high-fructose corn syrup 
consumption – so called “therapeutic lifestyle changes.”   
When pharmacological treatment is indicated, the choice of drug and drug class is determined by the underlying 
cause of hypertension and the comparative side-effect profiles of the medications. When choosing a drug within a 
particular class, practical issues such as frequency of drug dosing (daily dosing preferred), availability at local 
pharmacies, insurance formulary agents, and/or availabilities of low-cost generics should also be considered as they 
have important effects on adherence. Antihypertensive medication should be initiated at a starting dose and 
gradually increased to effect. If ineffective at maximum dosing, an additional medication with a complementary 
mechanism of action can be added [52].  
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Table 1. Causes of Hypertension 
  
 
Note: Relatively more common causes of hypertension are listed in bold. 
More important in 
younger patients 
 
 Idiopathic hypertension of 
prematurity 
 Renal artery or venous thrombosis 
 Congenital anomalies of the kidney 
and urinary tract (CAKUT) 
 Coarctation of the aorta 
 Congenital adrenal hyperplasia  
(11β- hydroxylase deficiency)  
 Medication effect 
 Pain 
 Pyelonephritis/renal scarring 
 Acute urinary tract obstruction 
 Chronic kidney disease 
 Glomerulonephritis 
 Acute kidney injury 
 Renal artery stenosis 
 Licorice intoxication 
 Monogenic hypertension (Liddle 
syndrome, AME, GRA, etc.) 
 Hyperthyroidism 
 Hypercalcemia 
 Paraneoplastic effects 
(pheochromocytoma, neuroblastoma) 
 Increased central nervous system 
sympathetic outflow 
 Increased intracranial pressure 
 Substance abuse  
 Primary hypertension 
More important in 
adolescents 
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Table 2. Selected antihypertensive drugs for management of outpatient hypertension in patients 1-17 years of age [1, 53-58]. 
Class Drug Dose Dosing Interval 
Calcium-
Channel Blocker 
Amlodipinea Initial: 0.05-0.1 mg/kg/day, up to 5 mg/day 
Maximum: 0.6 mg/kg/day, up to 10 mg/day  
Daily 
Extended-release 
nifedipineb 
Initial: 0.25-0.5 mg/kg/day, up to 60 mg/day 
Maximum: 3 mg/kg/day up to 120 mg/day 
Daily-BID 
Other available drugs in this class include isradipine, felodipine, verapamil, and diltiazem. 
ACE Inhibitor Captoprila, c   Initial: 0.9-1.5 mg/kg/day up to 40 mg/dayd 
Maximum: 6 mg/kg/day 
TID 
Enalaprila Initial: 0.08 mg/kg/day, up to 5 mg/day 
Maximum: 0.6 mg/kg/day, up to 40 mg/day 
Daily-BID 
Lisinoprila Initial: 0.07 mg/kg/day, up to 5 mg/day 
Maximum: 0.6 mg/kg/day, up to 40 mg/day 
Daily 
Other available drugs in this class include benazepril, fosinopril, and quinapril. 
Angiotensin-
receptor blocker 
(ARB) 
Losartanb Children ≥ 6 years of age: 
Initial: 0.7 mg/kg/day, up to 50 mg/day 
Maximum: 1.4 mg/kg/day, up to 100 mg/day 
Daily 
Valsartana Children 1-5 years of age, weighing ≥ 8 kg: 
Initial: 0.4 mg/kg/day  
Maximum: 3.4 mg/kg/day up to 40 mg/dose if <18 kg, up to 
80 mg/dose if ≥18 kg. 
Children 6-16 years of age:  
Initial: 1.3 mg/kg/day up to 40 mg/day 
Maximum: 2.7 mg/kg/day up to 160 mg/day 
Daily 
Other available drugs in this class include candesartan, irbesartan, and telmisartan. 
Thiazide 
Diuretics 
Chlorthalidoneb Initial: 0.3 mg/kg/day up to 12.5 mg/dayd 
Maximum: 2 mg/kg/day up to 50 mg/day 
Daily 
Chlorothiazidea Initial: 10-20 mg/kg/day 
Maximum: Age <2 years – 375 mg/day 
Age 2-12 years – 1000 mg/day 
Age >12 years – 2000 mg/day 
BID 
Hydrochlorothiazidea Initial: 1 mg/kg/day up to 25 mg/dayd 
Maximum: 3 mg/kg/day up to 50 mg/day 
Daily-BID 
Potassium-
Sparing Diuretic 
Spironolactonea Initial: 1 mg/kg/day up to 50 mg/dayd 
Maximum: 3.3 mg/kg/day up to 100 mg/day 
Daily-BID 
Other available drugs in this class include triamterene and amiloride.  
Beta-Blocker Atenolola Initial: 0.5-1 mg/kg/day up to 50 mg/day 
Maximum: 2 mg/kg/day up to 100 mg/day 
Daily-BID 
Metoprolol tartratea Initial: 1-2 mg/kg/day up to 100 mg/dayd 
Maximum: 6 mg/kg/day up to 200 mg/day 
BID 
Metoprolol succinate 
(extended release) 
Age ≥ 6 years: Initial: 1 mg/kg/day up to 50 mg/day 
Maximum: 2 mg/kg/day up to 200 mg/day 
Daily 
Propranolola Initial: 1-2 mg/kg/day up to 80 mg/dayd 
Maximum: 4 mg/kg/day up to 640 mg/day 
BID-TID 
Other available drugs in this class include bisoprolol/HCTZ 
Alpha and Beta-
Blocker 
Labetalola Initial: 1-3 mg/kg/day up to 200 mg/dayd 
Maximum: 10-12 mg/kg/day up to 1200 mg/day 
BID 
Direct 
Vasodilator 
Hydralazinea Initial: 0.75-1 mg/kg/day up to 25 mg/dayd 
Maximum: 7.5 mg/kg/day up to 200 mg/day 
QID 
Minoxidila Age <12 years: Initial: 0.1-0.2 mg/kg/day up to 5 mg/dayd 
Maximum: 50 mg/day  
Age ≥ 12 years: Initial: 5 mg/day 
Maximum: 100 mg/day 
Daily 
Peripheral alpha-
blocker 
Prazosinb Initial: 0.05-0.1 mg/kg/day up to 2 mg/dayd 
Maximum: 0.5 mg/kg/day up to 20 mg/day 
TID 
Other available drugs in this class include doxazosin and terazosin 
Central alpha-
agonist 
Clonidinea Initial: 5-10 mCg/kg/day up to 0.2 mg/dayd 
Maximum: 0.9 mg/day [53] 
Q8H-Q12H 
Patch: weekly 
22 
BID – twice daily, TID – three times daily. a Information on compounding a stable oral suspension available. b Not readily 
available in liquid form. c Infant/neonatal dose varies substantially from the child dose. d Maximum starting dose based on 
adult starting dose [56, 57]. The adult maximum dose should never be exceeded. 
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Table 3. Selected antihypertensive medications for treatment of severe hypertension in patients 1-17 years of age [1, 50, 59]. 
Class Drug Dose Route Comments 
Calcium-
Channel 
Blocker 
Nicardipine Infusion: 0.5-4 mCg/kg/min IV infusion May cause reflex tachycardia.  
Alpha and 
Beta-Blocker 
Labetalol Bolus: 0.2-1 mg/kg/dose up 
to 40 mg/dose 
Infusion: 0.25-3 mg/kg/hr 
IV bolus or 
infusion 
Asthma and overt heart failure 
are relative contraindications. 
Beta-Blocker Esmolol 100-500 mCg/kg/min IV infusion May cause profound 
bradycardia. 
Direct 
Vasodilator 
Hydralazine 0.1-0.6 mg/kg/dose up to 20 
mg/dose 
IV, IM Should be given every 4 hours 
when given as IV bolus. 
Sodium
Nitroprusside 
Initial: 0.3-0.5 mCg/kg/min 
Maximum: 10 mCg/kg/min 
IV infusion Monitor thiocyanate levels with 
prolonged use (>72 hours) or in 
renal failure; or co-administer 
with sodium thiosulfate. 
ACE Inhibitor Enaliprilat 5-10 mCg/kg/dose up to 
1.25 mg/doseb 
IV bolus Less useful for severe 
hypertension with significant 
symptoms; may cause prolonged 
hypotension and AKI, especially 
in neonates 
Oral agents – useful for patients with less significant symptoms 
Calcium-
Channel 
Blocker 
Isradipinea 0.05-0.1 mg/kg/dose up to 5 
mg/dose  
PO Immediate release formulation 
usually given every 6-8 hours. 
Direct 
Vasodilator 
Hydralazinea 0.25 mg/kg/dose up to 25 
mg/dose 
PO May be repeated every 4-6 hours 
if needed. 
Minoxidila 0.1-0.2 mg/kg/dose PO Most potent oral vasodilator, 
long-acting. 
Central Alpha 
Agonist 
Clonidinea,c 0.05-0.1 mg/dose, may be 
repeated up to 0.8 mg total 
dose
PO Side effects include dry mouth 
and drowsiness. 
IV – intravenous, IM – intramuscular, PO – by mouth/orally. a Information on compounding a stable oral suspension 
available. b Dosing and safety in pediatrics is not well-established. c Dose referenced to weight is not available. See table 3 
for oral clonidine dosing in non-urgent hypertension. 
